Synlogic, Inc. Declares Itself a 'Public Shell' Following Nasdaq Delisting
SYBX is trading near its 52-week low of $0.54 (15% above the low) on light trading volume (0.1× avg).
Summary
Synlogic, Inc. filed an amendment to its delisting 8-K, formally stating its belief that it is a 'public shell' and confirming its shares will trade on the OTCQB Venture Market.
Key Events · Legal and Risk Events · SYBX
-
Public Shell Status Declared
The company now explicitly states its belief that it is a 'public shell' under Nasdaq rules following its delisting.
-
Transition to OTCQB Venture Market
Shares are expected to be quoted on the OTCQB Venture Market of OTC Markets Group after delisting from Nasdaq.
-
Delisting Confirmed
Reaffirms the delisting of its common stock from Nasdaq, effective January 21, 2026, as previously disclosed on January 20, 2026.
Analysis · SYBX · Life Sciences
This amended 8-K provides critical new information by formally stating the company's belief that it is a 'public shell' under Nasdaq rules. This admission, following the recent Nasdaq delisting, significantly reinforces the negative investment thesis, indicating a lack of substantial operations or assets. While the delisting was previously disclosed, the explicit 'public shell' declaration confirms the dire state of the company and suggests a potential path towards liquidation or a reverse merger. The move to the OTCQB Venture Market is a further downgrade in trading venue, reflecting the company's diminished status.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 41% of the 324 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.33%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SYBX was trading at $0.62 on OTC in the Life Sciences sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $0.54 to $1.96. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.